406 related articles for article (PubMed ID: 26954482)
61. Effects of renin-angiotensin system blockade on mortality and hospitalization in heart failure with preserved ejection fraction.
Agarwal V; Briasoulis A; Messerli FH
Heart Fail Rev; 2013 Jul; 18(4):429-37. PubMed ID: 22678768
[TBL] [Abstract][Full Text] [Related]
62. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in hypertensive patients with myocardial infarction or heart failure: a systematic review and meta-analysis.
Ohtsubo T; Shibata R; Kai H; Okamoto R; Kumagai E; Kawano H; Fujiwara A; Kitazono T; Murohara T; Arima H
Hypertens Res; 2019 May; 42(5):641-649. PubMed ID: 30948834
[TBL] [Abstract][Full Text] [Related]
63. Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes.
Vart P; Vaduganathan M; Jongs N; Remuzzi G; Wheeler DC; Hou FF; McCausland F; Chertow GM; Heerspink HJL
Clin J Am Soc Nephrol; 2022 Dec; 17(12):1754-1762. PubMed ID: 36414316
[TBL] [Abstract][Full Text] [Related]
64. Should all patients at high cardiovascular risk receive renin-angiotensin system blockers?
Volpe M
QJM; 2012 Jan; 105(1):11-27. PubMed ID: 22011630
[TBL] [Abstract][Full Text] [Related]
65. Renin-Angiotensin System Blockade after Acute Kidney Injury (AKI) and Risk of Recurrent AKI.
Hsu CY; Liu KD; Yang J; Glidden DV; Tan TC; Pravoverov L; Zheng S; Go AS
Clin J Am Soc Nephrol; 2020 Jan; 15(1):26-34. PubMed ID: 31843974
[TBL] [Abstract][Full Text] [Related]
66. Treatment of diabetic kidney disease. A network meta-analysis.
Büttner F; Barbosa CV; Lang H; Tian Z; Melk A; Schmidt BMW
PLoS One; 2023; 18(11):e0293183. PubMed ID: 37917640
[TBL] [Abstract][Full Text] [Related]
67. Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis.
Tseng AS; Kunze KL; Lee JZ; Amin M; Neville MR; Almader-Douglas D; Killu AM; Madhavan M; Cha YM; Asirvatham SJ; Friedman PA; Gersh BJ; Mulpuru SK
Circ Arrhythm Electrophysiol; 2019 Jun; 12(6):e006951. PubMed ID: 31159582
[TBL] [Abstract][Full Text] [Related]
68. The role of renin inhibition in treating the hypertensive patient with diabetes: a summary of preclinical and clinical evidence.
Abdellatif AA
Expert Rev Cardiovasc Ther; 2012 Feb; 10(2):251-63. PubMed ID: 22292880
[TBL] [Abstract][Full Text] [Related]
69. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With Outcomes After Acute Kidney Injury.
Brar S; Ye F; James MT; Hemmelgarn B; Klarenbach S; Pannu N;
JAMA Intern Med; 2018 Dec; 178(12):1681-1690. PubMed ID: 30422153
[TBL] [Abstract][Full Text] [Related]
70. Blocking the renin-angiotensin system: dual- versus mono-therapy.
Ravandi A; Teo KK
Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
[TBL] [Abstract][Full Text] [Related]
71. Cardiovascular and renal protection in type 2 diabetes mellitus: the role of calcium channel blockers.
Nosadini R; Tonolo G
J Am Soc Nephrol; 2002 Nov; 13 Suppl 3():S216-23. PubMed ID: 12466317
[TBL] [Abstract][Full Text] [Related]
72. Comparative effectiveness of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers in patients with type 2 diabetes and retinopathy.
Shih CJ; Chen HT; Kuo SC; Li SY; Lai PH; Chen SC; Ou SM; Chen YT
CMAJ; 2016 May; 188(8):E148-E157. PubMed ID: 27001739
[TBL] [Abstract][Full Text] [Related]
73. Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial.
Bhandari S; Ives N; Brettell EA; Valente M; Cockwell P; Topham PS; Cleland JG; Khwaja A; El Nahas M
Nephrol Dial Transplant; 2016 Feb; 31(2):255-61. PubMed ID: 26429974
[TBL] [Abstract][Full Text] [Related]
74. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
Feng Y; Huang R; Kavanagh J; Li L; Zeng X; Li Y; Fu P
Am J Cardiovasc Drugs; 2019 Jun; 19(3):259-286. PubMed ID: 30737754
[TBL] [Abstract][Full Text] [Related]
75. The Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients With Diabetes.
Padwal R; Lin M; Eurich DT
J Clin Hypertens (Greenwich); 2016 Mar; 18(3):200-6. PubMed ID: 26289255
[TBL] [Abstract][Full Text] [Related]
76. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis.
Casas JP; Chua W; Loukogeorgakis S; Vallance P; Smeeth L; Hingorani AD; MacAllister RJ
Lancet; 2005 Dec; 366(9502):2026-33. PubMed ID: 16338452
[TBL] [Abstract][Full Text] [Related]
77. ACE inhibitor and angiotensin II type 1 receptor antagonist therapies in elderly patients with diabetes mellitus: are they underutilized?
Pappoe LS; Winkelmayer WC
Drugs Aging; 2010 Feb; 27(2):87-94. PubMed ID: 20104936
[TBL] [Abstract][Full Text] [Related]
78. Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers--a gap in evidence-based medicine.
Ball SG; White WB
Am J Cardiol; 2003 May; 91(10A):15G-21G. PubMed ID: 12781904
[TBL] [Abstract][Full Text] [Related]
79. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
Yang S; Zhao L; Mi Y; He W
Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
[TBL] [Abstract][Full Text] [Related]
80. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.
MacKinnon M; Shurraw S; Akbari A; Knoll GA; Jaffey J; Clark HD
Am J Kidney Dis; 2006 Jul; 48(1):8-20. PubMed ID: 16797382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]